WeightWatchers Discard Outdated Diet Plan
The development taking place everyday has made the international dieting Company, p change its fat and calorie-based points plan. They are now said to have adopted the new system since the old plan has...
View ArticleTeflaro gets FDA Approval for CABP and ABSSI Treatment
On Friday, ceftaroline fosamil (Teflaro), manufactured by Forest Laboratories Inc. has been shown green signal by the Food and Drug Administration to provide treatment to adults suffering from...
View ArticleNuedexta Obtains FDA Approval; Avanir Shares More than Double
The Food and Drug Administration (FDA) recently approved Nuedexta, a drug that will treat bouts of uncontrolled laughter or crying in patients with neurological disorders. Avanir Pharmaceuticals Inc.,...
View ArticlePfizer Makes Another Recall
Pfizer is reported to have widened the voluntary recall of its blockbuster cholesterol-fighting drug again. As per the company’s statement, an additional 38,000 bottles of the drug Lipitor have been...
View ArticleHikma Still has $500m to Spend on Expansion
There are several procurements to be made by Hikma Pharmaceuticals as it still is said to have some $500m war chest to spend. It is said to have bought Baxter International's US drugs unit...
View ArticleNovo Nordisk Plans to Discontinue Mixtard 30; Diabetics Concerned
Novo Nordisk has announced plans to drop Mixtard 30, an insulin drug, in order “to focus resources on developing the next generation of insulins”.Mixtard 30 closely resembles insulin made naturally by...
View ArticleBTG to pay £160m for buying Biocompatibles
The pharmaceutical group, renowned for its varisolve varicose veins treatment, BTG is going to add oncology products in its profile by capturing drug device group Biocompatibles, paying £160m.The...
View ArticleDespite Q4 losses, GSK may buy back shares
GlaxoSmithKline (GSK) Limited is expected to resume its share buyback programme on Thursday despite loss due to a massive legal charge in the fourth quarter. The investors who had urged GSK to adopt...
View ArticleSpin-offs might possible show a ray of hope for Pfizer site
With the US maker Pfizer announcing the shutdown of its research and development site at Sandwich in Kent, the decision came as a blow this week as around 2,400 jobs are at risk.The site, which has had...
View ArticleSanofi finally wins Genzyme deal
Ending months of uncertainty, the Sanofi-Aventis deal with Genzyme finally came to an end since Sanofit was able to buy out Genzyme for $74 per share. This means that a total of $20.1 billion is going...
View ArticleGSK the UK drug company faces charges for bribing Polish doctors
GlaxoSmithKline which is the largest drug company of UK supposedly bribed some doctors and now is going through a criminal investigation case in Poland, BBC Panorama has revealed.Today some fresh...
View ArticleReckitts Troubled Pharmaceutical Arm Posts Better –than-expected Sales Figures
Reckitt Benckiser the makers of Dettol and Durex condoms yesterday hinted towards follow-on of its pharmaceuticals arm that was much in trouble earlier. This happened as it posted a sales figure during...
View ArticlePfizer interested in AstraZeneca: report
American pharmaceuticals giant Pfizer Inc is reportedly mulling a plan to place a bid for struggling British drugs-maker AstraZeneca.While Pfizer hasn't revealed any such plan so far, London's Sunday...
View ArticleAstraZeneca’s acquisition will make lot of sense for Pfizer: says analyst
The recently published report about Pfizer's supposed interest in British drugmaker AstraZeneca has prompted many experts to predict that such a deal would make a lot of sense for the U. S....
View ArticleValeant working out cash-&-stock offer for Allergan
Valeant Pharmaceuticals International Inc. in partnership with Pershing Square Capital Management LP is reportedly trying to acquire Botox wrinkle treatment-maker Allergan Inc. in a cash-&-stock...
View ArticleAstraZeneca’s potential takeover by Pfizer may lead to thousands of job cuts
The potential takeover of British pharmaceuticals firm AstraZeneca by American drugs giant Pfizer has raised concerns about the future of British firm's employees.Pfizer, well-known for its erectile...
View ArticleBritish lawmakers anxiously watching Pfizer-AstraZeneca talks
British lawmakers are concerned about the future of AstraZeneca and thousands of its employees, as U. S.-based pharmaceuticals giant Pfizer is preparing a £60 billion (nearly $100bn) takeover bid for...
View ArticleTwo state leaders express concerns over Pfizer’s potential takeover of...
Governors of Delaware and Maryland have expressed their concerns over the impact of Pfizer Inc.'s proposed takeover of British pharmaceuticals giant AstraZeneca on workers as well as the states'...
View ArticleAstraZeneca is apparently not British
Amid ongoing political storm over Pfizer's potential takeover of British pharmaceuticals giant AstraZeneca, some analysts have pointed out that AstraZeneca is apparently not British.AstraZeneca is a...
View ArticlePfizer promises to keep British research jobs in the country
Pfizer Inc.'s chief executive Ian Read on Tuesday acknowledged that a potential takeover of AstraZeneca would lead to job losses, but it assured that the company's British research jobs would be kept...
View ArticleChina’ action against British executive may prompt firms to rethink their...
Chinese police's action against a British executive of GlaxoSmithKline Plc might cause some international companies to rethink their investment plans in the country. Sending a strong warning to the...
View ArticlePfizer-AstraZeneca deal is not inevitable: Pascal Soriot
Pfizer's takeover bid for AstraZeneca is not inevitable and the Anglo-Swedish pharmaceutical giant can create value for its shareholder on its own, according to AstraZeneca CEO Pascal Soriot's claims....
View ArticleAbbott agrees to acquire Latin America’s CFR Pharmaceuticals for $2.9bn
American pharmaceuticals & health care products firm Abbott Laboratories on Friday confirmed that it would acquire Chile-based CFR Pharmaceuticals SA in a $2.9 billion (£1.72 billion) deal.Abbott...
View ArticlePfizer raises its ‘final’ bid for AstraZeneca to £69bn
Pfizer CEO Ian Read on Sunday described the company's new proposal for AstraZeneca as "compelling" and cautioned that the American drugmaker would walk away if AstraZeneca didn't accept it.The U....
View Article
